Full Press Release Details
Inspira Technologies Unveils
Investor Deck Showcasing Revolutionary Advancement in Acute Respiratory Care
Ra'anana, Israel June 15, 2023 - Inspira Technologies
OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira Technologies"), a company aiming to
revolutionize acute respiratory care, is thrilled to present our latest investor deck (the "Investor Deck"), unveiling unparalleled
opportunities that have the potential to reshape the acute respiratory care landscape introducing empowered breathing without the use
INSPIRATM AI is embedded into the INSPIRA ART500
to target hyper-personalized patient care, providing empowered breathing without lungs. We believe that our technologies have the potential
to prevent the need for patients to be treated with mechanical ventilators that necessitate intubation and induced comas.
We continuously strive to push the boundaries of innovation, leveraging
advanced technologies to develop groundbreaking medical devices to increase and enhance the use of extracorporeal blood circulation, whereby
the patient's blood is circulated outside of the body for oxygen enrichment and carbon dioxide removal and is then returned to the
Our Investor Deck highlights our vision, achievements, our focus going
forward and what we believe are remarkable opportunities. In addition, our projected targets and milestones for the second half of 2023
include the submission of the INSPIRA ART100 to the U.S. Food and Drug Administration (the "FDA") via the 510(k) pathway,
additional strategic and distribution agreements for the INSPIRA ART500, the INSPIRA ART100 and the HYLA blood sensor.
We also aim to benefit from additional patent grants for the INSPIRA ART500 as well as broadening our collaborative relationships
and programs with key medical institutes.
Key Highlights of the Investor Deck include:
Revolutionary Acute Respiratory Care Innovations: The Investor
Deck showcases our cutting-edge extracorporeal blood circulation medical devices. With a deep understanding of the challenges faced by
healthcare providers and patients, we have focused our efforts on developing the INSPIRA ART500, an augmented respiration technology
designed to provide respiratory support, boosting oxygen saturation levels in minutes in patients while they are awake. To hyper-personalize
patient care, INSPIRATM AI is embedded into the INSPIRA ART500 to empower breathing without the use of lungs and prevent
the need for patients to be treated with mechanical ventilators that necessitate intubation and coma and result in mortality rates of
Addressing Critical Healthcare Challenges: Powered by INSPIRA
AI, the INSPIRA ART500 augmented respiration technology is designed to hyper-personalize patient care by continuously learning
the patient and devices in real-time to provide physicians with monitoring and predictive analytics.
Market Potential: As the demand for innovative respiratory medical
devices continues to grow, our market presents immense potential. The Investor Deck provides comprehensive insights into how we plan to
expand the extracorporeal blood sector with the INSPIRA ART500 powered by INSPIRA AI into an approximately $20 billion total
addressable market (based on internal Company projections), our competitive advantages, and projected growth opportunities for the Company.
We believe that our next-generation technologies position us at the forefront of this rapidly expanding industry.
"As the president and co-founder of Inspira Technologies, I am
delighted to share our latest update and unveil the Investor Deck that encapsulates our commitment to innovation and transformative healthcare
solutions," said Joe Hayon, Co-Founder and President of the Company. "This comprehensive overview demonstrates the extraordinary
opportunities that lie ahead and invites our stakeholders to join us in our pursuit of reshaping the future of respiratory healthcare."
The Investor Deck is now available for review on our website https://inspira-technologies.com/investor-relations/,
where interested parties can access detailed information about the exciting investment prospects within the medical device industry.
About Inspira Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical technology company in
the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRATM ART500),
designed to rebalance patient oxygen saturation levels. This technology potentially allows patients to remain awake during treatment while
reducing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced
coma. The Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity.
For more information, please visit our corporate website: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements
pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations
of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it
discusses the potential advantages and benefits of its products and technology, its vision, its belief that its technologies have the
potential to prevent the need for patients to be treated with mechanical ventilators that necessitate intubation and induced comas, the
impending submission and potential clearance of the INSPIRA ART100 to the FDA, planned strategic and distribution agreements for
the INSPIRA ART500, the INSPIRA ART100 and the HYLA blood sensor, its aim to benefit from additional patent grants
for the INSPIRA ART500 as well, its aim to broaden its collaborative relationships and programs with key medical institutes, the
INSPIRA ART500 projected ability to prevent the need for patients to be treated with mechanical ventilators, its insights into
how it plans to expand the extracorporeal blood sector with the INSPIRA ART500, projected growth opportunities, total addressable
market for its products and its belief that the next-generation technologies position it at the forefront of this rapidly expanding industry.
These forward-looking statements and their implications are based solely on the current expectations of the Company's management
and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in
the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions
to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated
events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors"
in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2022 filed with the U.S. Securities and Exchange
Commission (the "SEC"), which is available on the SEC's website, www.sec.gov
US Public Relations and Investor Relations
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
This technology has not been tested or used in humans and is subject
to regulatory approval.